Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Plus Cetuximab-beta in Third-Line RAS Wild-Type Metastatic Colorectal Cancer
NCT07724223Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, KL-140 in colorectal cancer (CRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jan 2026; status: recruiting.
02
Drugs
fruquintinibKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07724223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724223.